Regulatory Spine Theradaptive Secures FDA Approval to Advance OASIS Trial to Pivotal Study Evaluating OsteoAdapt® SP in Spinal Fusion byTim AllenApril 30, 2026
Biologics Spine Top Stories ATEC and Theradaptive Enter Strategic Partnership for Breakthrough Regenerative Technology in Spinal Fusion byJosh SandbergJanuary 12, 2026
Biologics Financial Theradaptive Appoints Daniel Wolf as Chief Financial Officer, Continuing Executive Transformation byTim AllenApril 22, 2025
Biologics Spine Theradaptive Announces Peer-Reviewed Publication in Spine of Preclinical Spinal Fusion Study of OsteoAdapt™ SP byTim AllenNovember 6, 2024
Biologics Financial Spine Theradaptive Secures Landmark Funding from Maryland Stem Cell Research Fund (MSCRF) to Support Human Clinical Trials byTim AllenMay 22, 2024
Biologics Spine Top Stories Theradaptive Strengthens Executive Team with Hire of Frank Vizesi as Chief Scientific Officer byTim AllenApril 16, 2024
Biologics Regulatory Spine Theradaptive to Expand Global Clinical Trials After Receiving Full Ethics Approval in Australia for OsteoAdapt SP byJosh SandbergFebruary 27, 2024
Biologics Extremities Spine Theradaptive Awarded DOD Clinical Trial Award of up to $7.4 Million byJosh SandbergSeptember 26, 2023
Biologics Extremities Spine 3D Systems & Theradaptive Establish Commercial Partnership to Advance Orthopedic & Soft Tissue Repair Using Breakthrough Regenerative Therapeutics byJosh SandbergAugust 7, 2023
Biologics Extremities Financial Spine U.S. Department of Defense Awards Theradaptive $4 Million Contract for Its OsteoAdapt Regenerative Therapeutic Program byJosh SandbergMarch 1, 2023
